ReviewCurrent rheumatology reports2011
Treatment of cutaneous lupus.
Review in Current rheumatology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 75 citations in OpenAlex.
- Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine axis-mediated recruitment of leukocytes that drive disease.Scientific reports · 2026Article
- Therapeutic Approaches for Cutaneous Lupus Erythematosus: a Changing Landscape of Clinical Trials.Journal of inflammation research · 2026Review
- Efficacy and safety of calcineurin inhibitors in cutaneous lupus: a systematic review and brief meta-analysis of recommended concentration, type, and outcomes.Annals of medicine and surgery (2012) · 2025Article
- Dapsone Use in Dermatology.American journal of clinical dermatology · 2024Review
- Article
- Cutaneous Lupus Erythematosus: Review and Considerations for Older Populations.Drugs & aging · 2024Review
- Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus.International journal of molecular sciences · 2022Review
- Polymeric dexamethasone prodrugs attenuate lupus nephritis in MRL/lpr mice with reduced glucocorticoid toxicity.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review.Annals of translational medicine · 2021Review
- Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis.Clinical rheumatology · 2021Review
- Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.Frontiers in immunology · 2020Review
- Gene Co-expression Networks Identifies Common Hub Genes Between Cutaneous Sarcoidosis and Discoid Lupus Erythematosus.Frontiers in medicine · 2020Article
- Article
- Current Insights Into The Management Of Discoid Lupus Erythematosus.Clinical, cosmetic and investigational dermatology · 2019Article
- Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.Journal of the American Academy of Dermatology · 2018Article
- Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus.Arthritis research & therapy · 2017Article
- Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Expert review of clinical immunology · 2016Review
- Current and emerging treatment options in the management of lupus.ImmunoTargets and therapy · 2016Review
- Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized.Dermatology and therapy · 2015Article
- Cutaneous lupus erythematosus: An update.Indian dermatology online journal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cutaneous lupus erythematosus (CLE) is an autoimmune inflammatory skin disease seen in patients with or without systemic lupus erythematosus. The management of CLE includes treatment and prevention of lesions as well as routine assessment for systemic disease. Treatment options include topical and systemic therapies. Topical therapies include corticosteroids and calcineurin inhibitors. Systemic therapies generally fall under one of three categories: antimalarials, immunomodulators (eg, dapsone and thalidomide), and immunosuppressives (eg, methotrexate and mycophenolate). Evidence for the treatment of CLE has been limited by few prospective studies and the lack of a validated outcome measure (until recently). There is good evidence to support the use of topical steroids and calcineurin inhibitors, although most of these trials have not used placebo or vehicle controls. There have been no randomized, placebo-controlled trials evaluating systemic therapies in the treatment of CLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.